Sorting and secreting insulin by expiration date – Newswise

Newswise A study in the Journal of Biological Chemistry describes a new way to determine the age of insulin-storage parcels, known as granules, and sheds light on how their age affects their release into the bloodstream. The findings could help experts better understand diabetes and fine-tune therapies for it.

Insulin is a hormone that manages the level of sugar, or glucose, in the bloodstream. It is secreted by the pancreas into the bloodstream when blood sugar levels rise. When insulin circulates in the bloodstream, muscle and other cells absorb glucose to use it as fuel, and so blood sugar levels decline. In Type 2 diabetes, formerly known as adult-onset diabetes, this process fails. Glucose builds up in the blood, either because the pancreas cannot produce enough insulin to keep up with dietary sugar intake or because the gland simply isnt working as it should.

About one in 10 Americans and more than 415 million people worldwide have diabetes, according to the Centers for Disease Control and Prevention. Up to 95% of them have Type 2. Treatment often requires painful and frequent insulin injections or the use of mechanical insulin pumps. There is no cure.

The researchers noted in their paper that existing therapies for diabetes increase insulin secretion without regard for insulin granule age. Accordingly, they wrote, these approaches are effective only for a short period.

Insulin is produced by -cells of the pancreas and stored in insulin granules, which are then organized into pools and finally secreted into the bloodstream. Pools of young insulin granules are preferred for secretion over pools of old ones, for reasons that remain unclear.

The scientists whose work was published in JBC wanted to learn more about how pancreatic cells can distinguish between pools with young or old insulin granules.

Current therapeutics do not take the existence of pools into consideration, said Melkam Kebede, an assistant professor at the University of Sydney who oversaw the study. By evolution, the (pancreatic) cells have determined what to secrete and what not. Understanding the mechanism and molecular differences between the pools definitely is going to lead us into something meaningful.

In their paper, the researchers describe a technique they developed to distinguish younger insulin granules from older ones. The scientists placed a fluorescent protein, called Syncollin-dsRedE5TIMER, into newly created insulin granules and used a laser and detector to visualize that marker. In younger granules, the marker emits a green fluorescent light; as granules get older, the marker begins to emit a red fluorescence.

The authors monitored the movements of and other changes in insulin granule pools and saw that, as predicted, both mouse and human cells preferentially release younger insulin granule pools into the bloodstream in response to glucose.

The researchers then set out to learn more about how pancreatic cells sort insulin granules into pools and release them when they are experiencing metabolic stress. The concern is that, when under stress, -cells could potentially lose their ability to distinguish young (granules) from old, they wrote in their paper.

The team isolated -cells from mice and simulated chronic low, high and normal blood sugar levels and found different glucose levels determine which pools of insulin granules, young or old, are secreted. They saw similar results when they used a common mouse model for Type 2 diabetes known as the db/dbmouse.

These findings are important, Kebede said, because all the drugs that affect insulin secretionjust push any granule within the cell and eventually fail. Older insulin granules are naturally degraded in normally functioning beta cells, noted lead author Belinda Yau of the University of Sydney, but, in diabetes, a greater percentage of insulin granule pools are secreted, and theres a mismatch in how theyre released.

Being able to visualize insulin granules as they age and understanding better how their age affectstheir secretion may lead to the discovery of new biomarkerscapable of indicating the development of diabetes and could help in the creation of therapies for Type 2 diabetes.

If we can understand what makes up the granules and makes them do what they do, we can figure out a way to target the things that slow down or speed up their secretion, Yau said.

##

DOI: 10.1074/jbc.RA120.012432

This research was conducted by scientists at the University of Sidney, the University of Chicago the Garvan Institute of Medical Research in Australia, St. Vincent's Institute in Australia, and the Centre for Transplant and Renal Research at Westmead Hospital in Australia. The work was supported by the National Health and Medical Research Council (NHMRC) of Australia grant ID GNT1139828.

##

About theJournal of Biological Chemistry

JBCis a weekly peer-reviewed scientific journal that publishes research "motivated by biology, enabled by chemistry" across all areas of biochemistry and molecular biology. To read the latest research inJBC, visithttp://www.jbc.org/.

About the American Society for Biochemistry and Molecular Biology

The ASBMB is a nonprofit scientific and educational organization with more than 11,000 members worldwide. Most members teach and conduct research at colleges and universities. Others conduct research in government laboratories, at nonprofit research institutions and in industry. The Society publishes three journals: the Journal of Biological Chemistry, the Journal of Lipid Research, and Molecular and Cellular Proteomics. For more information about ASBMB, visitwww.asbmb.org.

Read this article:
Sorting and secreting insulin by expiration date - Newswise

New Report Explored Global Carvacrol Market Demand Would Increase Rapidly by 2026 | COVID19 Impact Analysis | Key Players: SHUBH Flavour And…

The latest Carvacrolmarket report estimates the opportunities and current market scenario, providing insights and updates about the corresponding segments involved in the global Carvacrolmarket for the forecast period of 2020-2026. The report provides detailed assessment of key market dynamics and comprehensive information about the structure of the Carvacrolindustry. This market study contains exclusive insights into how the global Carvacrolmarket is predicted to grow during the forecast period.

The primary objective of the Carvacrol market report is to provide insights regarding opportunities in the market that are supporting the transformation of global businesses associated with Carvacrol. This report also provides an estimation of the Carvacrolmarket size and corresponding revenue forecasts carried out in terms of US$. It also offers actionable insights based on the future trends in the Carvacrolmarket. Furthermore, new and emerging players in the global Carvacrolmarket can make use of the information presented in the study for effective business decisions, which will provide momentum to their businesses as well as the global Carvacrolmarket.

Get Exclusive Sample copy on Carvacrol Market is available at https://inforgrowth.com/sample-request/6329485/carvacrol-market

The study is relevant for manufacturers, suppliers, distributors, and investors in the Carvacrolmarket. All stakeholders in the Carvacrolmarket, as well as industry experts, researchers, journalists, and business researchers can influence the information and data represented in the report.

Carvacrol Market 2020-2026: Segmentation

The Carvacrol market report covers major market players like SHUBH Flavour And Fragrances Pvt., Foreverest Resources Ltd, Weifang Union Biochemistry, Anhui Haibei Import & Export Co., Hairui Natural Plant Co., High Hope Intl Group, Jiangxi Baicao Pharmaceutical, Shree Bankey Behari Lal Aromatics, Fuzhou Farwell Import & Export Co., Kunshan Sainty Y.J.Y. Co., Xian Aladdin Biological Technology,

Carvacrol Market is segmented as below:

By Product Type: Natural Type, Synthetic Type,

Breakup by Application:Flavors and Fragrances, Food Additives, Pharmaceutical Intermediates, Other

Impact of COVID-19:CarvacrolMarket report analyses the impact of Coronavirus (COVID-19) on the Carvacrolindustry.Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost 180+ countries around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Carvacrolmarket in 2020.

The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor events restricted; emergency declared in many countries; massive slowing of the supply chain; stock market unpredictability; falling business assurance, growing panic among the population, and uncertainty about future.

COVID-19 can affect the global economy in 3 main ways: by directly affecting production and demand, by creating supply chain and market disturbance, and by its financial impact on firms and financial markets.

Download the Sample ToC and understand the COVID19 impact and be smart in redefining business strategies. https://inforgrowth.com/CovidImpact-Request/6329485/carvacrol-market

Global Carvacrol Market Report Answers Below Queries:

To know about the global trends impacting the future of market research, contact at: https://inforgrowth.com/enquiry/6329485/carvacrol-market

Key Questions Answered in this Report:

What is the market size of the Carvacrol industry?This report covers the historical market size of the industry (2013-2019), and forecasts for 2020 and the next 5 years. Market size includes the total revenues of companies.

What is the outlook for the Carvacrol industry?This report has over a dozen market forecasts (2020 and the next 5 years) on the industry, including total sales, a number of companies, attractive investment opportunities, operating expenses, and others.

What industry analysis/data exists for the Carvacrol industry?This report covers key segments and sub-segments, key drivers, restraints, opportunities and challenges in the market and how they are expected to impact the Carvacrol industry. Take a look at the table of contents below to see the scope of analysis and data on the industry.

How many companies are in the Carvacrol industry?This report analyzes the historical and forecasted number of companies, locations in the industry, and breaks them down by company size over time. The report also provides company rank against its competitors with respect to revenue, profit comparison, operational efficiency, cost competitiveness, and market capitalization.

What are the financial metrics for the industry?This report covers many financial metrics for the industry including profitability, Market value- chain and key trends impacting every node with reference to companys growth, revenue, return on sales, etc.

What are the most important benchmarks for the Carvacrol industry?Some of the most important benchmarks for the industry include sales growth, productivity (revenue), operating expense breakdown, the span of control, organizational make-up. All of which youll find in this market report.

Get Special Discount UP TO 50% for this Report:https://inforgrowth.com/discount/6329485/carvacrol-market

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:Address: 6400 Village Pkwy suite # 104, Dublin, CA 94568, USAContact Name: Rohan S.Email:[emailprotected]Phone: US: +1-909-329-2808UK: +44 (203) 743 1898

Read more here:
New Report Explored Global Carvacrol Market Demand Would Increase Rapidly by 2026 | COVID19 Impact Analysis | Key Players: SHUBH Flavour And...

Artificial intelligence in embryo selection: a reality thanks to IVIRMA Global – PRNewswire

VALENCIA, Spain, July 6,2020 /PRNewswire/ --As spectacular and futuristic as it may seem, using Artificial Intelligence to automatically analyze embryos in a standardized way to improve pregnancy rates is already a reality. This is confirmed by an IVIRMA Global study entitled 'A universal algorithm is available in last generation time-lapse incubators: embryo score provided by the KIDScoreD5 is strongly correlated with chromosomal status and clinical outcomes'.

IVIRMA Global has already participated in the development of the EmbryoScope (incubator with time-lapse technology) from its beginnings, helping in its evolution and laying the foundations for automatic embryo selection. In its latest development, EmbryoScope presents its newest software system, KIDScoreD5, which automatically performs embryo selection and classification.

The study has been carried out over the last three years and has become the most extensive case study in the history of embryology to date (more than 20,000 embryos and more than 3,000 patients have been analyzed). In the study, IVIRMA Global has demonstrated that universal, standardized and automatic embryo selection is a reality for the field of embryology. As the study's principal researcher, Dr. Marcos Meseguer, scientific supervisor of IVI Valencia, comments, "The KIDScoreD5 system automatically classifies embryos using Artificial Intelligence, it detects and evaluates all the steps in the development of the embryo and also classifies its morphology".

Dr. Meseguer points out that, "We have seen that the KIDScoreD5 system makes an assessment to distinguish between those embryos that are more likely to be chromosomally normal, called euploid embryos, and those that are not, called aneuploid embryos." Based on the score the system gives each embryo, we know its probability of gestation and the possibility of taking a healthy baby home.

The KIDScoreD5 system analyzes the embryos automatically classifying them from one to ten depending on their quality and morphology. Since automated embryo selection is more accurate than manual selection, the probability of a successful pregnancy is directly linked to the percentage score and, therefore, the patient has a greater chance of success.

Main values of the study and the KIDScoreD5 system

About IVIRMA Global

IVI was founded in 1990, as the first medical institution in Spain fully dedicated to assisted reproduction. Since then it has helped with the birth of more than 200,000 babies thanks to the application of the latest technologies. In early 2017, IVI merged with RMANJ, becoming the largest assisted reproduction group in the world. It currently has more than 65 clinics in 9 countries and is the leading centre for reproductive medicine. http://www.ivi.es- http://www.rmanetwork.com.

For more information:

SOURCE IVIRMA Global

Home

See the rest here:
Artificial intelligence in embryo selection: a reality thanks to IVIRMA Global - PRNewswire

Breakthrough study demonstrates the ‘re-awakening’ of the ovaries and achieves pregnancy in woman with premature ovarian failure using stem cells -…

LONDON, July 6, 2020 /PRNewswire/ -- IVIRMA, a global network of fertility clinics and world-leading pioneer in fertility research, are presenting a breakthrough study at the 36th Congress of the European Society of Human Reproduction and Embryology (ESHRE) today, demonstrating the possibility of 're-awakening' the ovaries in women under 40 (38 years and below) with the lowest reproductive reserve at the ovarian level.1 The ASCOT technique (involving infusion of stem cells in the ovarian artery), which has recently been shown to be successful in low-responder patients, has now shown it can achieve pregnancy in a woman with premature ovarian failure (POF).1

The study, 'Bone marrow derived stem cells restore ovarian function and fertility in premature ovarian insufficiency women. Interim report of a randomized trial: mobilization versus ovarian injection',1 which is still ongoing, includes two study arms: one using the ASCOT technique, that is, the infusion of stem cells in the ovarian artery* and, second, a less invasive option consisting of mobilising the stem cells, and allowing them to reach the ovaries through the bloodstream directly. The preliminary results have shown that ovarian follicle development was achieved in both groups, with some patients re-starting menstruation, and a decrease in menopausal symptoms. As a result of this procedure, embryos were obtained in 2 out of the 10 participants, and even one pregnancy through the ASCOT technique was achieved.

Dr. Diaz, Medical Director, IVI London, a leading fertility specialist and co-pioneer of the world's first womb transplant, commented, "We are truly excited by these very promising results achieving ovary re-awakening and pregnancy using stem cells in a woman who previously may not have had the option to conceive using her own eggs. We continually strive to pioneer on the cutting-edge of fertility research, as we know how harrowing it can be for every person struggling to conceive. These new techniques may give us potential new options for women with premature ovarian failure, in addition to those with low ovarian reserve."

It is estimated that 1 in 100 women under 40 years of age suffer from premature ovarian failure (POF) in the UK. 2.5% of all patients with POF are adolescents.2 This premature cessation of ovarian activity is one of the most challenging scenarios in terms of reproduction and can be devastating. Now, thanks to the findings of this study, led by Dr. Sonia Herraiz, researcher at the IVI Foundation-IIS la Fe, Spain and Dr. Nuria Pellicer, gynaecologist at Hospital la Fe in Valencia, Spain, there might be hope for women suffering from this fertility issue.

Dr. Nuria Pellicer, Gynaecologist, Hospital la Fe, Valencia, Spain added, "So far, we obtained embryos in 2 of the 10 patients included and one 37-week pregnancy in the ASCOT arm, in patients with almost no chance of successful pregnancy with classic in vitro fertilisation procedures. We found that both arms promoted the development of follicles, and some patients have even recovered their menstruation, thus reducing menopausal symptoms However, these are preliminary results of an ongoing study, so we remain cautious until the study is complete. We aim to develop a technique that is as minimally invasive as possible over time and standardise it so that it can be implemented in all our clinics. We would like to make it possible to offer any woman who wishes to become a mother the possibility of doing so, even when her reproductive circumstances are unfavourable."

"This is a very encouraging line of research in which we will continue to work with a single goal: to improve assisted reproduction techniques and treatments in order to obtain the best results, however difficult the reproductive prognosis may seem," concluded Dr. Herraiz, researcher at the IVI Foundation-IIS, la Fe, Spain.

More About the Study1

In addition to this research, IVI are presenting three more studies at the ESHRE Congress:

These new techniques and other research conducted by IVI is translated and applied to the treatments available in their clinics across the world, which is in turn reflected in the achieved results. The London clinic has achieved 71.4% clinical pregnancy rates per embryos transferred in women under the age of 386 and recent data shows that with PGT-A genetic screening the evolutive pregnancy rate is 57% in women undergoing treatment at IVI London as compared to the national average of 42%.7 Furthermore, 100% of these pregnancies have been achieved through single embryo transfer, eliminating chances of multiple pregnancy and the complications that arise with it.7

More about the ASCOT technique development: 3 babies and 6 pregnancies achieved so far in low-responder patients

To date, 3 babies and 6 pregnancies have been achieved using the ASCOT technique for ovarian rejuvenation in low-responder patients with low ovarian reserve, pioneered by IVIRMA Global. The technique involves transplanting bone marrow-derived stem cells (BMDSC) into the ovarian artery, achieving a partial reversal of ageing of the ovary, the organ responsible for ovulation, and activating the dormant follicles that would otherwise remain arrested in the ovary. After its first phase in animal models to test the effectiveness of the technique with stem cells, this study went to its second phase in low-responder patients. A total of 20 patients had their stem cells mobilized, extracted from peripheral blood and implanted back into the ovary in order to reverse the ageing process and activate the dormant follicles. This technique has improved ovarian function biomarkers in 81% of low responder patients. In addition, spontaneous pregnancies occurred. In view of the success of this phase, the next stage was undertaken, which consisted of recruiting women under 38 years of age, this time with early ovarian failure (a situation with a worse reproductive prognosis that of low responders). From here the above-mentioned study arose.

IVIRMA Global and IVI London, UK

IVI was founded in 1990, as the first medical institution in Spain fully dedicated to Assisted Reproduction. Since then it has helped with the birth of more than 200,000 babies thanks to the application of the latest Assisted Reproduction technologies. In early 2017, IVI merged with RMANJ, becoming the largest Assisted Reproduction group in the world. It currently has more than 65 clinics in 9 countries and is the leading centre for Reproductive Medicine. In 2016 IVI opened its doors in London, located in the heart of the medical district.www.rmanetwork.comhttps://ivi-fertility.co.uk/

References

Logo - https://mma.prnewswire.com/media/1200377/IVI_Logo.jpg

Read the rest here:
Breakthrough study demonstrates the 're-awakening' of the ovaries and achieves pregnancy in woman with premature ovarian failure using stem cells -...

Adelaide fertility software launches in the UK, Europe – InDaily

adelaide Monday July 06, 2020

An Adelaide-based company that uses artificial intelligence to increase the chance of pregnancy through IVF has launched its software application in the UK and Europe.

Life Whisperer, the fertility arm of AI healthcare company Presagen, commercialised its flagship product in Australia in late January and released it through a distributor into India, Sri Lanka and Bangladesh last month.

Approvals are also being sought to sell the software tool in Japan, Southeast Asia and the US, where it has conducted a number of clinical trials.

Last weeks launch into the UK and Europe is a major step in the three-and-a-half-year journey for the product, which was forced into a COVID-19 hiatus from March to May when many of the worlds fertility clinics closed their doors.

Get InDaily in your inbox. Daily. The best local news every workday at lunch time.

Thanks for signing up to the InDaily newsletter.

Presagen currently has 15 staff and small offices in San Francisco and London to drive the global expansion.

Founder and CEO Dr Michelle Perugini said the company had strong connections in the UK and Europe and a number of clinics were already trialling the product in the region.

She said getting clinics on board as commercial customers was the next stage.

Regulatory approval in the UK and Europe represents a significant opportunity for Life Whisperer to expand its global presence, and we are very much looking forward to working with clinics and patients across the region, supported from our London Offices, she said.

Its a secure web-based application that is completely scalable so we can set up new clinics within minutes anywhere in the world.

Life Whisperer co-founders Dr Jonathan Hall (left), Dr Michelle Perugini and Dr Don Perugini. Picture: Matt Loxton.

The Embryo Viability Application for IVF clinics uses artificial intelligence to analyse images of embryos to assist clinicians to identify which embryo will likely lead to a pregnancy.

By selecting the best embryo, Life Whisperer aims to shorten the time to pregnancy and improve outcomes for couples undergoing IVF treatment.

An international study recently published in the journal Human Reproduction involved blind evaluation of 1600 IVF embryos.

Life Whisperer was shown to perform 25 per cent better than traditional manual methods of embryo assessment by highly experienced embryologists.

The technology will be showcased on Tuesday night Australian time at the 36th Annual Meeting of the European Society of Human Reproduction and Embryology, which is being held online this year.

Internationally renowned fertility expert Matthew (Tex) VerMilyea from Ovation Fertility (USA) will present Life Whisperers latest advances in AI for IVF at the event where Presagen will also have a virtual exhibition booth .

Dr Perugini said Presagen was planning a significant capital raise this year to drive growth.

She said the company was looking forward to working with IVF clinics across the globe to offer Life Whisperer to patients at a low cost, meaning more couples could gain more certainty in embryo selection and achieve success sooner, with fewer IVF cycles.

Life Whisperer is poised to become the global gold standard embryo pre-screening tool in IVF, supporting the clinical decision about which embryo is most viable.

Dr Perugini and Presagen CTO Dr Jonathan Hall are both past winners of InDailys 40 Under 40 Awards, which recognises South Australias top business leaders aged under 40.

Nominations are still openfor this years 40 Under 40 Awards with judging to commence in August before the awards are held in October.

In times like these InDaily provides valuable, local independent journalism in South Australia. As a news organisation it offers an alternative to The Advertiser, a different voice and a closer look at what is happening in our city and state for free. Any contribution to help fund our work is appreciated. Please click below to donate to InDaily.

Powered by PressPatron

Original post:
Adelaide fertility software launches in the UK, Europe - InDaily

HFEA publishes 2018 trends in fertility treatment – BioNews

6 July 2020

The Human Fertility and Embryology Authority (HFEA)has published its latest analysis on trends in fertility treatment, based on data from across the UK in 2018.

Headline findings include an increase in IVFsuccess rates, a surge in eggand embryofreezing, and a decrease in NHSfunding for fertility treatments.

Sally Cheshire, chair of the HFEA, said: 'While fertility treatment is never a guarantee for a baby, we are pleased to see that birth rates have increased over the years and the average birth rate is now steady at 23 percent. Whilst this leaves many couples without their longed-for family after treatment, these small year-on-year increases are important for the sector to build on.'

In 2018 about 54,000 patients underwent 68,724 fresh and frozen IVFcycles and 5,651 donor insemination cycles at HFEA licensed fertility clinics across the UK. IVF birth rates increased for all patient groups under the age of 43 over time. Patients below the age of 35 had a birth rate of 31 percent per transferred embryo (23 percent for all patients), an increase from only nine percent in 1991, when HFEA was established.

Age remains a key factor for IVF success, with a birth rate below five percent for women over 43 who use their own eggs.

Multiple pregnancy, one of the main risk factors of IVF, has for the first time fallen to eight percent, as it has become clear that implanting more than one embryo has no significant impact on the chance of live birth.

The report also states that the number of patients choosing embryo and egg storage cycles increased five-fold from 1400 in 2013 to 9000 in 2018. The number of women freezing unfertilisedeggs has also climbed from 569 in 2013 to 2000 in 2018. Frozen embryo transfers are now more successful than fresh ones, although only by a small margin.

Sarah Norcross from the Progress Educational Trust said: 'The women we have spoken to value motherhood and having a family is really important to them and so they are choosing to freeze their eggs as a back-up plan in case they need them in the future. Of course, they may not need them as they may find a partner and get pregnant the old-fashioned way. I think there is a greater awareness of egg freezing as a reproductive choice and also of the biological clock and so women are choosing to invest money in trying to improve their reproductive options'.

The level of NHS funding for fertility treatment varies across the UK: In Scotland, 60 percent of fertility treatments are funded by the NHS, but in England where funding is controlled locally by clinical commission groups (CCGs), this figure has fallen below 30 percent in some areas.

'What is hugely disappointing is the continued fall in NHS-funded cycles... Whilst the Nice [National Institute forHealthand Care Excellence] guidance states that all eligible couples should be entitled to three full cycles (including the use of frozen embryos)' said Professor Adam Balen, the Royal College of Obstetricians and Gynaecologists spokesperson on reproductive medicine. 'IVF is cost effective and has shown to be an economic benefit to society.'

Read more here:
HFEA publishes 2018 trends in fertility treatment - BioNews

Immunity to the coronavirus is ‘fragile’ and ‘short lived,’ immunologist warns – CNBC

It is not a "safe bet" to rely on immunity to Covid-19 as a strategy for coping with the pandemic, one expert has warned, adding that herd immunity strategies were "probably never going to work."

Speaking to CNBC's "Squawk Box Europe" on Monday, Danny Altmann, professor of immunology at Imperial College London, said that in towns and cities where there had been coronavirus infections, only 10% to 15% of the population was likely to be immune.

"And immunity to this thing looks rather fragile it looks like some people might have antibodies for a few months and then it might wane, so it's not looking like a safe bet," he said. "It's a very deceitful virus and immunity to it is very confusing and rather short lived."

He also raised questions about the likely success of so-called herd immunity when a population is allowed some exposure to the virus in order to buildimmunity among the general population which has been cited by health officials in Sweden, which controversially avoided a lockdown.

Despite a global race to find a vaccine for the coronavirus, experts remain uncertain about whether the antibodies present in people who have had the virus actually provide immunity to reinfection.

Top White House health advisor Dr. Anthony Fauci speculated last month that if Covid-19 behaved like other coronaviruses, there "likely isn't going to be a long duration of immunity" from antibodies or a vaccine. Meanwhile, the WHO has stated that it remains unclear whether those who have already caught the virus once will be immune to getting it again.

Imperial College London's Altmann said on Monday that he was expecting a second wave of Covid-19, and that although governments were much better prepared for a resurgence in infections, the situation remained "very, very scary."

"Anybody who thinks that it has got more mild or gone away or that somehow the problem's going to solve itself is kidding themselves," he told CNBC. "It's still a very lethal virus, it still infects people very, very readily. And I think humanity isn't used to dealing with those realities."

He also emphasized that it was difficult to make predictions about if or when an effective vaccine for Covid-19 might be identified.

"The devil is in the detail, vaccines aren't that easy," Altmann said. "There's more than 100 in trial at the moment and many things can go wrong along the way. I place no bets at the moment myself."

David King, former chief scientific adviser to the U.K. government, warned in an interview with Sky News on Sunday that the U.K. would have an additional 27,000 deaths from Covid-19 if it stayed on its current trajectory. To date, 44,305 people have died from Covid-19 in the U.K., according to data compiled by Johns Hopkins University.

Altmann told CNBC that he agreed with this projection "to some extent," claiming that a lot of scientists, immunologists and vaccine experts still felt "very scared" about the pandemic.

He acknowledged that policymakers needed to find a balance between protecting public health and preventing socioeconomic disasters, but added: "We need to continue to be led by the science and the medicine and do the right thing. And doing the right thing means everything you can do to block transmission."

The new strain of coronavirus, first reported to the WHO in late December, has infected more than 11.4 million people and killed 534,825 globally to date, according to data compiled by Johns Hopkins University.

Tedros Adhanom Ghebreyesus, director-general of the World Health Organization, warned last week that the pandemic was accelerating around the world as economies began to reopen.

View original post here:
Immunity to the coronavirus is 'fragile' and 'short lived,' immunologist warns - CNBC

More calls for masks in the Hillsborough County Schools – Tampa Bay Times

TAMPA In advance of Tuesdays meeting of the Hillsborough County School Board, proponents of mandatory masks at school have continued to call for a stricter policy.

A letter to that effect went out over the weekend, signed by close to 200 people who identified themselves as physicians. We are printing the petition below.

So far, the district has said it is providing a limited number of reusable masks for children, but only encouraging their use.

PREVIOUS: Parents: Children should wear masks to school

Calls went out over Facebook for concerned citizens to gather outside the School Board building at 3:30 p.m. for a socially distanced, masked protest. Those interested were also asked to address the board during the public comment period. The initial announcement said the Hillsborough Classroom Teachers Association was behind this event. But union spokeswoman Stephanie Baxter-Jenkins said it was not a union-organized event, and a notice went out later clarifying that fact.

Either way, interest is high on the subject of masks.

Tuesdays board meeting begins at 4 p.m. at 901 E Kennedy Boulevard.

The letter:

Dear Superintendent Davis and Hillsborough County School Board:

As a concerned group of Pediatricians and Physicians serving children and teachers/staff in Hillsborough County, we urge you to mandate masks and face coverings in our public schools during this global pandemic of COVID-19.

The American Academy of Pediatrics recommendations in COVID-19 Planning Considerations: Guidance for School Re-entry (attached) indicate that masks and face coverings are high priority for elementary, middle, and high school students.

Exemptions to wearing masks for children with individualized education plans or with medical conditions that would prohibit safe and effective use of masks should be handled on a case-by-case basis. Though some of our youngest (pre-school and kindergarten) students may be initially unable to wear a mask the full school day, with time and proper modeling, many of these young students may be able to properly wear masks when social distancing is not possible.

At a population level, masks are undeniably useful at reducing cases of COVID-19 in our community. Mask usage is most effective when all persons wear them, and families that chose to not wear masks endanger others by risking asymptomatic or pre-symptomatic spread of the virus. Mandating masks in our schools can: 1) prevent spread of viral infection that will compromise the health of children, their families and school employees, 2) reduce outbreaks that will threaten school or classroom closure 3) prevent unnecessary time off work for parents, staff and teachers, and 4) save health care resources of our pediatric practices which will be tasked with testing and clearing students for return to school.

We appreciate the hard work of our educators and administrators in Hillsborough County. We value the guidance and commitment of our School Board to make schools safe, accessible, and academically robust. We hope that you will follow the recommendations of the American Academy of Pediatrics and make masks and face coverings required for students and faculty in our schools.

https://services.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/clinical-guidance/covid-19-planning-considerations-return-to-in-person-education-in-schools/

Sincerely,

1. Anne M. Lenz, MD (Pediatrician, Endocrinology)

2. Tiffany Hernandez, MD (General Pediatrician)

3. Kiersten Hartlage, MD (General Pediatrician)

4. Leigh J. Ruth, MD (Child and Adolescent Psychiatry)

5. Sapnalaxmi Amin, MD (Family Medicine)

6. Rachel Irby, MD (Internal Medicine, Infectious disease)

7. Alisa Pierce-Kee, MD (General Pediatrician)

8. Grace Dougan, MD (Pediatrician, Endocrinology)

9. Rebecca Pruitt, MD (General Pediatrician)

10. Karina A. Parilo, MD (Family Medicine)

11. Shikha Sharma, MD (Internal Medicine)

12. Crystal Jacovino, DO (Internal Medicine)

13. Elisa Thompson, MD, FAAFP (Family Medicine)

14. Lindsey Bowser, MD (Family Medicine)

15. Melinda Murphy, MD, FAAP (General Pediatrician)

16. Monique Sajjad, DO (Hematology-Oncology)

17. Eric Schilling, DO (Pulmonary Critical Care)

18. Paul Nanda, MD (Urgent Care Medicine)

19. Leslie Turner, MD (Pathology)

20. Edgard Janer, MD (Rheumatology)

21. Richard Wilde, MD, FAAP (General Pediatrician)

22. Preeti Kallu, MD (Internal Medicine)

23. Heather Simpson Khanna, MD (Adult and Adolescent Psychiatry)

24. Amanda Sergay, MD (Dermatology)

25. Lilly Chang, MD, DDS (Pediatric CranioMaxillofacial Surgery)

26. Eva Gupta, MD (Hematology-Oncology)

27. Parul Aneja, MD (Infectious Disease)

28. Anil Chopra, MD (Infectious Disease)

29. Kate Knupp, MD (Internal Medicine, Pediatrics)

30. Catherine Kubiak, MD (Allergy Immunology)

31. Maria del Pilar Cekan, MD (Family Medicine)

32. Alex Anton, MD (General Pediatrics)

33. Jacqueline Hartman, MD, FAAP (General Pediatrician)

34. Christina Paulson, MD (General Pediatrician)

35. Shara Young, MD (OB-Gyn)

36. Catherine Hough-Telford, MD (General Pediatrician)

37. Rachel Rapkin, MD, MPH (OG-Gyn)

38. Andrew Galligan, MD (Pediatric Hematology-Oncology)

39. Lisa Rush, MD (General Pediatrician)

40. Matt Minick, MD (General Pediatrician)

41. Francesca Sabia, MD, FAAP (General Pediatrician)

42. Eliana Piedrahita-Llano, MD (General Pediatrician)

43. Gwennaelle A. Wilson, MD, MPH, FAAP (General Pediatrician)

44. Mary Chrisochos, DO, FAAP (Pediatrician)

45. Jennifer White, MD (Psychiatry)

46. Bhumi Kumar, DO, FAAP (General Pediatrician)

47. Elizabeth Harris, MD (General Pediatrician)

48. Natasha Hughes, MD (General Pediatrician)

49. Nay Hoche, MD (OB-Gyn)

50. Madhurima Sanka, DO (Pediatrics, Allergy and Immunology)

51. Sheila Mak, DO (General Pediatrician)

52. Rachel Epstein, DO, FAAD, FACMS (Dermatology)

53. Celia Williams, DO (General Pediatrics)

54. Solimar Salud, MD (General Pediatrics)

55. Lauren Sequeira, MD (Family Medicine)

56. David Van, DO (Family Medicine)

57. Ria Ross, DO (Dermatology)

58. Jennifer Pesce, MD (General Pediatrician)

59. Tracey DeLucia, MD, PhD, FAAOS (Pediatric Orthopedic Surgery)

60. Danita Wongchantara, MD (Primary Care Medicine and Pediatrics)

61. Julie Dekle, MD (General Pediatrician)

62. Ashley McPhie, MD (General Pediatrician)

63. Sara Ansari, DO (General Pediatrician)

64. Anjali Nirmalani-Gandhy, MD (Child Psychiatry)

65. Ana Maria Oliva, MD (Ophthalmology)

66. Beena Wilkins, MD (General Pediatrician)

67. Rosmery Victoria, DO (Family Medicine)

68. Jennifer Sawka, MD (General Pediatrician)

69. Carolyn Robinson, MD, FAAP (Pediatrician, Pulmonology)

70. Theresa Dam Lohmiller, MD (Family Medicine)

71. Jean Del Valle, MD (Child Psychiatry)

72. Laura Cruse, MD (Rheumatology)

73. Denise Edward, MD (Internal Medicine- Pediatrics)

74. Tsu-Hui Lin, MD (Pediatrics, Endocrinology)

75. Kelly Grabbe, DO (Emergency Medicine)

76. Lisa Hayes, DO (General Pediatrician)

77. Maliena Longley, MD (Pediatrics, Allergy and Immunology)

78. Dolores Razman, MD (General Pediatrician)

79. Michelle Mendoza, MD (Emergency Medicine)

80. Julie Hallanger Johnson, MD (Endocrinology)

81. Lisa Champoux-Rhoden, MD (General Pediatrician)

82. Kimberly Hartney, MD (Psychiatry)

83. Marsha Ramsay, MD, FAAP (General Pediatrician)

84. Shahla Escobar, MD (Pediatric Anesthesiology)

Read this article:
More calls for masks in the Hillsborough County Schools - Tampa Bay Times

Aichi Cancer Center and NEC Aimed at Advanced Cancer Immunotherapy – AiThority

Through the Fusion of AI and Experimental Immunology

Aichi Cancer Center(1) and NEC Corporation announced the launch of fundamental research aiming to realize the promise of advanced personalized cancer immunotherapy by improving the performance of NECs neoantigen prediction system and developing predictive biomarkers for patient stratification through the fusion of AI and experimental immunology.

This research aims to identify suitable neoantigen for vaccine use by using the neoantigen prediction system which NEC has been working on and the screening techniques using T cells for neoantigen from Aichi Cancer Center. In addition, this research aims to develop biomarkers for patient stratification using AI based on analytical data on a tumor immune microenvironment and clinical data.

The partners will realize the promise of advanced personalized cancer immunotherapy which boosts the immune system especially in combination with immune checkpoint inhibitors (ICIs).

Recommended AI News: Amazon Web Services (AWS) Launches New Space Technology Segment

Although the ICIs showed a certain degree of therapeutic success in cancer therapeutics, the therapeutic effect is limited to few cases. Previous studies have suggested that there is a significant correlation between tumor neoantigen load and the clinical efficacy of ICIs. Accordingly, the immunotherapy could improve the therapeutic efficacy if the brakes on the immune system are disabled, and at the same time, the immune responses to neoantigens are accelerated. The important things for realizing effective cancer immunotherapies are 1.) the selection of neoantigens that harness the immune system and 2.) the patient stratification in treatment planning for ICI therapy, cancer vaccine therapy, and their combination therapy.

The Division of Translational Oncoimmunology at the Aichi Cancer Center has been conducting translational research using patient samples in collaboration with the departments of Thoracic Surgery and Thoracic Oncology at the Aichi Cancer Center Hospital. Specifically, this division specializes in experimental immunology and focuses on analyzing the immune microenvironment and the tumor-specific immune responses of each patient.

NEC is actively working on applied research in the drug development field using AI and has developed a unique AI-based neoantigen prediction system. NEC was accepted into the Tumor neoantigEn SeLection Alliance (TESLA) consortium given the uniqueness of this system and became the first Japanese company to join TESLA, founded and managed by the Parker Institute for Cancer Immunotherapy and the Cancer Research Institute.

Recommended AI News: Fujitsu And NetApp Introduce Data Management Infrastructure For HPC

1. Performance improvement of the neoantigen prediction systemAichi Cancer Center and NEC will identify neoantigens recognized by T cells by using both the neoantigen prediction system and the immunological experimental approach. In the future, NEC will improve the performance of the neoantigen prediction system by using this high-quality data.

2. Development of biomarkers for patient stratificationAichi Cancer Center and NEC will comprehensively analyze the tumor immune microenvironment of each patient. This research aims to develop biomarkers for patient stratification using AI based on clinical information, genetic mutation, gene expression, and experimental data obtained from the experiments described above.

Aichi Cancer Center will aim to carry out clinical trials of cancer immunotherapy. The clinical trials of cancer immunotherapy will be conducted at Aichi Cancer Center Hospital, and additional research will be conducted at Aichi Cancer Center Research Institute. The hospital and research institute will work together as a comprehensive cancer center.

NEC has been conducting applied research in the drug development field using AI for about 20 years. Through this joint research, NEC will accelerate its AI-driven drug development business by improving the performance of neoantigen prediction systems and developing biomarkers for patient stratification.

(1) Aichi Cancer CenterDesignated by Japans Minister of Health, Labour and Welfare as a hub hospital for cancer genome medical care.(2) NEC becomes the first Japanese company to join the TESLA consortiums fight against cancerhttps://www.nec.com/en/press/201905/global_20190514_01.html

Recommended AI News: AiThority Interview With Pankaj Chowdhry, CEO And Founder At FortressIQ

Share and Enjoy !

Read more:
Aichi Cancer Center and NEC Aimed at Advanced Cancer Immunotherapy - AiThority

Taoiseach fears international travel will reignite spread of coronavirus – Belfast Telegraph

Taoiseach Micheal Martin says there are fears that international travel will cause a resurgence in coronavirus and reiterated advice that people should not travel overseas.

he Cabinet is meeting on Monday to discuss the restrictions, although agreen list of countries where it is safe to travel to and from without having to quarantine is not expected to be published until July 20.

Mr Martin said: The travel advisory for the last while had been strong that its not advisable to travel overseas. We have to put public health first. That is the overarching issue.

Today the Cabinet will meet and make a formal decision on travel. We had a Cabinet sub-committee on Covid on Friday. The public health advice is extremely cautious now in relation to opening up for travel.

Close

The Cabinet is meeting to discusss the restrictions (Julien Behal/PA)

PA

Asked about when the Government will publish a list of green countries where it will be safe for Irish people to travel, Mr Martin said the matter was under constant review because the situation is changing very rapidly.

He said the Government is drawing up the list of countries, but noted there are countries where there are high numbers of cases.

We have countries that would have made the safe list two weeks ago wouldnt make it today, so the overarching objective is to suppress the virus and keep it down. There is a fear international travel could reignite the virus, he told Corks 96FM.

Meanwhile, Professor Kingston Mills said asking people travelling into Ireland from abroad to self-isolate for 14 days is not working.

That restriction was supposed to be lifted on Thursday of this week, but it is now expected to be extended until July 20 and then reviewed every two weeks thereafter.

Prof Mills, professor of experimental immunology and head of the Centre for the Study of Immunology at Trinity Biomedical Sciences Institute in Dublin, said Ireland has done well in suppressing the spread of coronavirus but allowing unrestricted travel into the country would unravel this.

Were one of the countries with the lowest levels of the virus in Europe and were an island. We have a chance to do even better than we have done in terms of completely eliminating the virus and preventing any further surges of the virus, he told RTEs Morning Ireland.

The idea of non-mandatory self isolation is not really working as I understand there are a significant amount of people not self-isolating or they are not being followed up.

People are effectively ignoring the advice from Government not to travel because you only have to look at the number of flights going in and out of Dublin to see that.

Close

People arriving in Ireland are expected to self-quarantine for 14 days (Brian Lawless/PA)

PA

Prof Mills said there are some European countries that may be safe to travel in and out from but he noted there are cities in the US where there are high numbers of cases.

Theres flights coming into Ireland from places like Chicago where they have a significant number of cases. If you have unrestricted flights coming in and people are not self isolating when they get here, then you are asking for trouble in terms of the virus resurging.

One more person has died with Covid-19 in Ireland on Sunday.

There has now been a total of 1,741 related deaths in the country, the National Public Health Emergency Team said.

PA

Originally posted here:
Taoiseach fears international travel will reignite spread of coronavirus - Belfast Telegraph